Molecular Partners (NASDAQ:MOLN) Shares Down 7.1%

Molecular Partners AG (NASDAQ:MOLNGet Free Report)’s share price dropped 7.1% during mid-day trading on Tuesday . The stock traded as low as $3.90 and last traded at $3.90. Approximately 1,067 shares traded hands during trading, a decline of 93% from the average daily volume of 15,105 shares. The stock had previously closed at $4.20.

Wall Street Analysts Forecast Growth

Separately, JPMorgan Chase & Co. dropped their price objective on Molecular Partners from $6.60 to $4.50 and set a “neutral” rating on the stock in a report on Tuesday, December 5th.

Get Our Latest Stock Analysis on MOLN

Molecular Partners Stock Performance

The company has a market cap of $141.77 million, a price-to-earnings ratio of -1.84 and a beta of 0.77. The company’s 50 day moving average price is $4.34 and its 200 day moving average price is $4.30.

Hedge Funds Weigh In On Molecular Partners

An institutional investor recently bought a new position in Molecular Partners stock. Susquehanna International Group LLP acquired a new stake in shares of Molecular Partners AG (NASDAQ:MOLNFree Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 33,660 shares of the company’s stock, valued at approximately $218,000. Susquehanna International Group LLP owned about 0.09% of Molecular Partners as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 26.55% of the company’s stock.

Molecular Partners Company Profile

(Get Free Report)

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317 which is in Phase I clinical trials, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.

Recommended Stories

Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.